![Henning Walczak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Henning Walczak
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Apogenix AG
![]() Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Fundador | 25/11/2009 | - |
Historial de carrera de Henning Walczak
Antiguos cargos conocidos de Henning Walczak.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
German Cancer Research Center
![]() German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Corporate Officer/Principal | 01/01/1998 | - |
Estadísticas
Internacional
Alemania | 3 |
Operativa
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 2 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Apogenix AG
![]() Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
German Cancer Research Center
![]() German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Health Services |
- Bolsa de valores
- Insiders
- Henning Walczak
- Experiencia